Case number 2019-1323
Janssen Oncology, Inc. v. Amerigen Pharmaceuticals > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 20, 2019 | 11 | Mandate issued to the United States District Court for the District of New Jersey (19-1147, 19-1148) and United States Patent and Trademark Office (19-1323, 19-1324, 19-1325). Service as of this date by the Clerk of Court. [615845] [19-1147, 19-1148, 19-1323, 19-1324, 19-1325] [MJL] [Entered: 06/20/2019 02:59 PM] (0) |
| May 14, 2019 | 9 | OPINION filed for the court by Moore, Circuit Judge; Wallach, Circuit Judge and Chen, Circuit Judge. Precedential Opinion. [607100] [19-1147, 19-1148, 19-1323, 19-1324, 19-1325] [JAB] [Entered: 05/14/2019 10:13 AM] (0) |
| May 14, 2019 | 10 | JUDGMENT filed. DISMISSED in Nos. 2019-1147, 2019-1148, 2019-1323, 2019-1324; AFFIRMED in No. 2019-1325. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [607103] [19-1148, 19-1323, 19-1324, 19-1325] [JAB] [Entered: 05/14/2019 10:20 AM] (0) |
| Jan 3, 2019 | 8 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [5], docketing statement Docket No. [6], certificate of interest Docket No. [7], ERROR: The entry of appearance [5], docketing statement [6], and certificate of interest [7] were submitted in trailer case 19-1323. Filings must be submitted in lead appeal 19-1147 only. CORRECTION: Please ensure future filings are submitted only in lead appeal 19-1147. Any further submissions in 19-1323 will be non-compliant. No further action is required on this entry as compliant versions were also filed in the lead appeal. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [575594] [JAL] [Entered: 01/03/2019 11:45 AM] (0) |
| Jan 2, 2019 | 5 | Entry of appearance for William D. Hare as principal counsel for Appellee Amerigen Pharmaceuticals Limited. Service: 01/02/2019 by email. [575350] [19-1323] [William Hare] [Entered: 01/02/2019 03:24 PM] (0) |
| Jan 2, 2019 | 6 | Docketing Statement for the Appellee Amerigen Pharmaceuticals Limited. Service: 01/02/2019 by email. [575351] [19-1323] [William Hare] [Entered: 01/02/2019 03:26 PM] (0) |
| Jan 2, 2019 | 7 | Certificate of Interest for the Appellee Amerigen Pharmaceuticals Limited. Service: 01/02/2019 by email. [575354] [19-1323] [William Hare] [Entered: 01/02/2019 03:28 PM] (0) |
| Dec 27, 2018 | 4 | Certified list from the United States Patent and Trademark Office. Service: 12/27/2018 by email. [574709] [JAL] [Entered: 12/27/2018 11:39 AM] (0) |
| Dec 20, 2018 | 2 | ORDER filed. The stay in the district court appeals is lifted. The district court appeals and the Board appeals are consolidated for purposes of briefing and argument. Each of the briefs shall include the full captions of the appeals as reflected above. The motion to exceed the word limit [573039-2] is denied. The court strikes appellants’ opening brief [569440-2] in the district court appeals filed on December 3, 2018 and sets the briefing schedule. (See order for more details). Cross-appellants are directed to inform this court no later than 12:00 p.m. on December 21, 2018 as to whether they wish to dismiss their cross-appeals. The USPTO is directed to transmit the certified lists within seven days from the date of filing of this order. (Per Curiam). Service as of this date by the clerk of court. [573570] [19-1323, 19-1324, 19-1325] [JAL] [Entered: 12/20/2018 02:09 PM] (0) |
| Dec 20, 2018 | 3 | Note to file: The following cases are associated: 19-1147 Lead with 19-1323, 19-1324, and 19-1325 Member Cases. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. Entries of Appearance for Argentum Pharmaceuticals LLC, Actavis Laboratories FL, Inc., Sun Pharmaceuticals Industries, Ltd., Sun Pharmaceuticals Industries Inc., and Iancu due 01/03/2019. Certificates of Interest for Argentum Pharmaceuticals LLC, Actavis Laboratories FL, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharmaceuticals Industries Inc. due on 01/03/2019. Docketing Statements for Argentum Pharmaceuticals LLC, Actavis Laboratories FL, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharmaceuticals Industries Inc. due 01/03/2019. Appellants' consolidated principal brief is due 01/18/2019 [573591] [19-1147, 19-1323, 19-1324, 19-1325] [JAL] [Entered: 12/20/2018 02:41 PM] (0) |
| Dec 19, 2018 | 1 | Appeal docketed. Received: 12/19/2018. [573090] Entry of Appearance due 01/02/2019. Certificate of Interest is due on 01/02/2019. Docketing Statement due 01/02/2019. Certified List due on 01/28/2019. [JAL] [Entered: 12/19/2018 01:38 PM] (63) |
